IMR Press / RCM / Volume 13 / Issue 1 / DOI: 10.3909/ricm0583

Reviews in Cardiovascular Medicine (RCM) is published by IMR Press from Volume 19 Issue 1 (2018). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with MedReviews, LLC.

Open Access Review
Emerging Therapies for Residual Risk
Show Less
1 Department of Cardiovascular Sciences, East Carolina University Brody School of Medicine, Greenville, NC
Rev. Cardiovasc. Med. 2012, 13(1), 24–31; https://doi.org/10.3909/ricm0583
Published: 30 March 2012
Abstract
The role of statins in reducing the risk of coronary artery disease is well established. The use of statins in patients at high risk for cardiovascular disease has reduced the incidence of major clinical events by 25% to 40%. However, despite aggressive statin therapy and the achievement of target low-density  lipoprotein cholesterol levels, the residual risk of cardiovascular events remains high. This review investigates emerging therapies to target the residual risk of cardiovascular events with concurrent statin therapy.
Keywords
Statins
Residual risk
Cardiovascular disease
Benchmark
Share
Back to top